Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/132488
Full metadata record
DC FieldValueLanguage
dc.creatorDias, A-
dc.creatorSantos, D-
dc.creatorCoelho, T-
dc.creatorAlves-Ferreira, M-
dc.creatorSequeiros, J-
dc.creatorAlonso, I-
dc.creatorSousa, A-
dc.creatorLemos, C-
dc.date.accessioned2021-03-03T17:42:40Z-
dc.date.available2021-03-03T17:42:40Z-
dc.date.issued2019-
dc.identifier.issn2328-9503-
dc.identifier.urihttps://hdl.handle.net/10216/132488-
dc.description.abstractObjectives: Transthyretin (TTR) familial amyloid polyneuropathy (FAP) (OMIM 176300) shows a variable age-at-onset (AO), including within families. We hypothesized that variants in C1QA and C1QC genes, might also act as genetic modifiers of AO in TTR-FAP Val30Met Portuguese patients. Methods: We analyzed DNA samples of 267 patients (117 families). To search for variants, all exons and flanking regions were genotyped by automated sequencing. We used generalized estimating equations (GEEs) to take into account the nonindependency of AO among relatives. Intensive in silico analyses were performed, using various software to assess miRNAs target sites, splicing sites, transcription factor binding sites alterations, and gene–gene interactions. Results: Two variants for C1QA gene, GA genotype of rs201693493 (P < 0.001) and CT genotype of rs149050968 (P < 0.001), were significantly associated with later AO. In silico analysis demonstrated, that rs201693493 may alter splicing activity. Regarding C1QC, we found three statistically significant results: GA genotype of rs2935537 (P = 0.003), GA genotype of rs201241346 (P < 0.001) and GA genotype of rs200952686 (P < 0.001). The first two were associated with earlier AO, whereas the third was associated with later-onset. Interpretation: C1QA was associated with later onset, whereas C1QC may have a double role: variants may confer earlier or later AO. As found in a study in Cyprus, we confirmed the role of complement C1Q genes (and thus of inflammation) as modulator of AO in Portuguese patients with TTR-FAP Val30Met.pt_PT
dc.description.sponsorshipWe would like to thank FEDER funds, through the Programa Operacional Factores de Competitividade – COMPETE 2020 and by Nacional funds through the FCT – Fundação para a Ciência e a Tecnologia [COMPETE: POCI-01-0145-FEDER-007440]. This work was supported by grants of Fundação para a Ciência e Tecnologia, FCT [PTDC/SAU GMG/100240/2008 and PEsT], co-funded by ERDF and COMPETE; and by Financiamento Plurianual de Unidades de Investigac¸a˜ o (FCT). DS is the recipient of a FCT fellowship [SFRH/BD/91160/2012]. MAF is recipient of a FCT fellowship [SFRH/BD/101352/2014].-
dc.language.isoengpt_PT
dc.publisherWileypt_PT
dc.relationinfo:eu-repo/grantAgreement/FCT/5876-PPCDTI/100240/PT; info:eu-repo/grantAgreement/FCT/SFRH/SFRH%2FBD%2F91160%2F2012/PT-
dc.relation.ispartofseriesAnnals of clinical and translational neurology, vol. 6(4), p. 748-754pt_PT
dc.rightsopenAccesspt_PT
dc.source.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.subject.meshAdult; Age of Onset; Aged; Amyloid / genetics; Amyloid / metabolism; Amyloid Neuropathies, Familial / complications; Amyloid Neuropathies, Familial / diagnosis; Amyloid Neuropathies, Familial / metabolism; Female; Genotype; Humans; Male; Membrane Glycoproteins / genetics; Middle Aged; Mutation / genetics; Polymorphism, Single Nucleotide / genetics; Prealbumin / genetics; Receptors, Complement / genetics-
dc.titleC1QA and C1QC modify age-at-onset in familial amyloid polyneuropathy patientspt_PT
dc.typeArtigo em Revista Científica Internacionalpt_PT
dc.contributor.uportoInstituto de Investigação e Inovação em Saúdept_PT
dc.identifier.doi10.1002/acn3.748-
dc.relation.publisherversionhttps://onlinelibrary.wiley.com/doi/full/10.1002/acn3.748-
Appears in Collections:I3S - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
ACN3-6-748.pdf130.85 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.